{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:59:25Z","timestamp":1792645165947,"version":"4.5.0"},"reference-count":247,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1999,8]]},"DOI":"10.1023\/a:1006348907994","type":"journal-article","created":{"date-parts":[[2002,12,21]],"date-time":"2002-12-21T20:36:27Z","timestamp":1040502987000},"page":"285-311","source":"Crossref","is-referenced-by-count":104,"title":["Antiestrogens \u2013 Tamoxifen, SERMs and Beyond"],"prefix":"10.1007","volume":"17","author":[{"given":"Kapil","family":"Dhingra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"247379_CR1","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0092-8674(87)90581-2","volume":"51","author":"V Kumar","year":"1987","unstructured":"Kumar V, Green S, Stack G, Berry M, Jin J-R, Chambon P: Functional domains of the human estrogen receptor. Cell 51: 941\u2013951, 1987","journal-title":"Cell"},{"key":"247379_CR2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/39645","volume":"389","author":"AM Brzozowski","year":"1997","unstructured":"Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753\u2013758, 1997","journal-title":"Nature"},{"key":"247379_CR3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0092-8674(89)90031-7","volume":"59","author":"L Tora","year":"1989","unstructured":"Tora L, White J, Brou C, Tassett D, Webster N, Scheer E, Chambon P: The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59: 477\u2013487, 1989","journal-title":"Cell"},{"key":"247379_CR4","first-page":"21","volume":"8","author":"MT Tzukerman","year":"1994","unstructured":"Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP: Human estrogen 304 receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intranolecular regions. Mot Endocrinol 8: 21\u201330, 1994","journal-title":"Mot Endocrinol"},{"key":"247379_CR5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0092-8674(88)90552-1","volume":"54","author":"NJG Webster","year":"1988","unstructured":"Webster NJG, Green S, Jin JR, Chambon P: The hormonebinding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54: 199\u2013207, 1988","journal-title":"Cell"},{"key":"247379_CR6","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1002\/j.1460-2075.1990.tb07469.x","volume":"9","author":"M Berry","year":"1990","unstructured":"Berry M, Metzger D, Chambon P: Role of the two activating domains of the estrogen receptor in the cell-type and promoter-context dependent agonist activity of the antiestrogen 4-hydroxytamoxifen. EMBO J 9: 2811\u20132818, 1990","journal-title":"EMBO J"},{"key":"247379_CR7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/j.1460-2075.1989.tb03526.x","volume":"8","author":"NJG Webster","year":"1989","unstructured":"Webster NJG, Green S, Tasset D, Panglikitmongkol M Chambon P: The transcriptional activation function located in the hormone binding domain of the human estrogen receptor is not encoded in a single exon. EMBO J 8: 1441\u20131446, 1989","journal-title":"EMBO J"},{"key":"247379_CR8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/mend.11.6.0008","volume":"11","author":"JD Norris","year":"1997","unstructured":"Norris JD, Fan DJ, Kerner SA, McDonnell DP: Identification of a third autonomous activation domain within the human estrogen receptor. Mol Endocrinol 11: 747\u2013754, 1997","journal-title":"Mol Endocrinol"},{"key":"247379_CR9","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1073\/pnas.93.12.5925","volume":"93","author":"GGJM Kuiper","year":"1996","unstructured":"Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93: 5925\u20135930, 1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"247379_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1615\/CritRevEukarGeneExpr.v7.i1-2.30","volume":"7","author":"BA Lieberman","year":"1997","unstructured":"Lieberman BA: The estrogen receptor activity cycle: dependence on multiple protein-protein interactions. Crit Rev Eukaryotic Gene Expression 7: 43\u201359, 1997","journal-title":"Crit Rev Eukaryotic Gene Expression"},{"key":"247379_CR11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1095\/biolreprod58.3.627","volume":"58","author":"CL Smith","year":"1998","unstructured":"Smith CL: Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod 58: 627\u2013632, 1998","journal-title":"Biol Reprod"},{"key":"247379_CR12","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1126\/science.270.5241.1491","volume":"270","author":"S Kato","year":"1995","unstructured":"Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491\u20131496, 1995","journal-title":"Science"},{"key":"247379_CR13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000055253","volume":"55","author":"S Kato","year":"1998","unstructured":"Kato S, Kitamoto T, Masuhiro Y, Yanagisawa J: Molecular mechanism of a cross-talk between estrogen and growthfactor signaling pathways. Oncology 55: 5\u201310, 1998","journal-title":"Oncology"},{"key":"247379_CR14","doi-asserted-by":"crossref","first-page":"13317","DOI":"10.1074\/jbc.273.21.13317","volume":"273","author":"PB Joel","year":"1998","unstructured":"Joel PB, Traish AM, Lannigans DA: Estradiol-induced phosphorylation of serine 118 is in the estrogen receptor is independent of p42\/p44 mitogen-activated protein kinase. J Biol Chem 273: 13317\u201313323, 1998","journal-title":"J Biol Chem"},{"key":"247379_CR15","doi-asserted-by":"crossref","first-page":"10132","DOI":"10.1073\/pnas.94.19.10132","volume":"94","author":"JM Trowbridge","year":"1997","unstructured":"Trowbridge JM, Rogatsky I, Garabedian MJ: Regulation of estrogen receptor transcriptional enhancement by the cyclinA\/ Cdk2 complex. Proc Natl Acad Sci USA 94: 10132\u201310137, 1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"247379_CR16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0092-8674(90)90343-D","volume":"60","author":"SE Fawell","year":"1990","unstructured":"Fawell SE, Lees JA White R, Parker MG: Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 60: 953\u2013962, 1990","journal-title":"Cell"},{"key":"247379_CR17","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0092-8674(86)90705-1","volume":"46","author":"L Klein-Hitpass","year":"1986","unstructured":"Klein-Hitpass L, Schorpp M, Wagner U, Ryffel CU:An estrogen responsive element derived from the 50 flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 46: 1053\u20131061, 1986","journal-title":"Cell"},{"key":"247379_CR18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0092-8674(88)90017-7","volume":"55","author":"V Kumar","year":"1988","unstructured":"Kumar V, Chambon P: The estrogen receptor binds tightly to its response element as a ligand-induced homodimer. Cell 55: 145\u2013156, 1988","journal-title":"Cell"},{"key":"247379_CR19","doi-asserted-by":"crossref","first-page":"12519","DOI":"10.1016\/S0021-9258(18)31419-4","volume":"268","author":"JD Furlow","year":"1993","unstructured":"Furlow JD, Murdoch FE, Gorski J: High affinity binding of the estrogen receptor to a DNA response element does not require homodimer formation or estrogen. J Biol Chem 268: 12519\u201312525, 1993","journal-title":"J Biol Chem"},{"key":"247379_CR20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/edrv-17-6-587","volume":"17","author":"M Beato","year":"1996","unstructured":"Beato M, Sanchez-Pacheco A: Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev 17: 587\u2013609, 1996","journal-title":"Endocr Rev"},{"key":"247379_CR21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0955-0674(97)80066-X","volume":"9","author":"CK Glass","year":"1997","unstructured":"Glass CK, Rose DW, Rosenfeld MG: Nuclear receptor coactivators. Curr Opin Cell Biol 9: 222\u2013232, 1997","journal-title":"Curr Opin Cell Biol"},{"key":"247379_CR22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo Y, Gholami Z, Shaffer D, Bayer S, Wray C, Bogden R, Dayanath P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66\u201371, 1994","journal-title":"Science"},{"key":"247379_CR23","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.284.5418.1354","volume":"284","author":"S Fan","year":"1999","unstructured":"Fan S, Wang J-A, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM: BRCAI inhibition of estrogen receptor signaling in transfected cells. Science 284: 1354\u20131356, 1999","journal-title":"Science"},{"key":"247379_CR24","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1126\/science.273.5279.1222","volume":"273","author":"NN Yang","year":"1996","unstructured":"Yang NN, Venugopalan M, Hardikar S, Glasebrook A: Identification of an estrogen response element activated by metabolites of 17\u03b2-estradiol and raloxifene. Science 273: 1222\u20131225, 1996","journal-title":"Science"},{"key":"247379_CR25","doi-asserted-by":"crossref","first-page":"14103","DOI":"10.1016\/S0021-9258(19)85214-6","volume":"268","author":"A Philips","year":"1993","unstructured":"Philips A, Chalbos D, Rochefort H: Estradiol increases and antiestrogens antagonize the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos or c-jun synthesis. J Biol Chem 268: 14103\u201314108, 1993","journal-title":"J Biol Chem"},{"key":"247379_CR26","doi-asserted-by":"crossref","first-page":"16651","DOI":"10.1074\/jbc.273.27.16651","volume":"273","author":"SK Lee","year":"1998","unstructured":"Lee SK, Kim HJ, Na SY, Kim TS, Choi HS, Im SY, Lee JW: Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. J Biol Chem 273: 16651\u201316654, 1998","journal-title":"J Biol Chem"},{"key":"247379_CR27","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.2047861","volume":"252","author":"RF Power","year":"1991","unstructured":"Power RF, Lydon JP, Conneely OM, O'Malley BW: Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 252: 1546\u20131547, 1991","journal-title":"Science"},{"key":"247379_CR28","doi-asserted-by":"crossref","first-page":"10882","DOI":"10.1074\/jbc.272.16.10882","volume":"272","author":"OWJ Prall","year":"1997","unstructured":"Prall OWJ, Sarcevic B, Musgrove EA, Watts CKW, Sutherland RL: Estrogen-induced activation of CDK4 and CDK2 during G(1>S phase progression is accompanied by increased cyclin D1 expression and decreased cyclindependent kinase inhibitor association with cyclin E-CDK2.J Biol Chem 272: 10882\u201310894, 1997","journal-title":"J Biol Chem"},{"key":"247379_CR29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00689680","volume":"31","author":"CKW Watts","year":"1994","unstructured":"Watts CKW, Sweeney KJE, Walters A, Musgrove EA, Sutherland RL: Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cells. Breast Cancer Res Treat 31: 95\u2013105, 1994","journal-title":"Breast Cancer Res Treat"},{"key":"247379_CR30","first-page":"1804","volume":"9","author":"CKW Watts","year":"1995","unstructured":"Watts CKW, Brady A, Sarcevic B, DeFazio A, Musgrove EA, Sutherland RL: Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 9: 1804\u20131813, 1995","journal-title":"Mol Endocrinol"},{"key":"247379_CR31","first-page":"4039","volume":"17","author":"MD Planassilo","year":"1997","unstructured":"Planassilo MD, Weinberg RA: Esaogen-dependent cyclin ECDK2 activation through p21 redistribution. Mol Cell Biol 17: 4039\u20134069, 1997","journal-title":"Mol Cell Biol"},{"key":"247379_CR32","first-page":"119","volume-title":"Hormone Dependent Cancer","author":"CKW Watts","year":"1996","unstructured":"Watts CKW, Wilcken NRC, Hamilton JA, Sweeney KJE, Musgrove EA, Sutherland RL: Mechanisms of antiestrogen, progestin\/antiprogestin, and retinoid inhibition of cell cycle progression in breast cancer cells. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormone Dependent Cancer. Marcel Dekker, New York, 1996, pp 119\u2013140"},{"key":"247379_CR33","first-page":"4561","volume":"55","author":"JM Gudas","year":"1995","unstructured":"Gudas JM, Nguyen H, Li T, Cowan KH: Hormone-dependent regulation of BRCAI in human breast cancer cells. Cancer Res 55: 4561\u20134565, 1995","journal-title":"Cancer Res"},{"key":"247379_CR34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.onc.1200808","volume":"14","author":"JR Marks","year":"1997","unstructured":"Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, Mc-Donnell DP, Wiseman RW, Futreal PA, Iglehart JD: BRCA1 305 expression is not directly responsive to estrogen. Oncogene 14: 115\u2013121, 1997","journal-title":"Oncogene"},{"key":"247379_CR35","first-page":"35","volume":"63","author":"BR Westley","year":"1998","unstructured":"Westley BR, Clayton SJ, Daws MR, Molloy CA, May FEB: Interactions between the oestrogen and insulin-like growth factor signalling pathways in the control of breast epithelial cell proliferation. Biochem Soc Symp 63: 35\u201344, 1998","journal-title":"Biochem Soc Symp"},{"key":"247379_CR36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0960-0760(91)90185-8","volume":"40","author":"B Van der Burg","year":"1991","unstructured":"Van der Burg B, De Groot RP, Isbr\u00fccker L, Kruijer W, De Laat SW: Oestrogen directly stimulates growth factor signal tranaduction pathways in human breast cancer cells. J Steroid Biochem Mol Biol 40: 215\u2013221, 1991","journal-title":"J Steroid Biochem Mol Biol"},{"key":"247379_CR37","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0215(19960822)69:4<335::AID-IJC17>3.0.CO;2-4","volume":"69","author":"SI Helle","year":"1996","unstructured":"Helle SI, Holly JMP, Tally M, Hall K, Van der Stappen J, Lonning PE: Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 69: 335\u2013339, 1996","journal-title":"Int J Cancer"},{"key":"247379_CR38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/j.1460-2075.1992.tb05141.x","volume":"11","author":"PS Danielian","year":"1992","unstructured":"Danielian PS, White R, Lees JA, Parker MG: Identification of a conserved region required for hormone-dependent transcriptional activation by steroid hormone receptors. EMBO J 11: 1025\u20131033, 1992","journal-title":"EMBO J"},{"key":"247379_CR39","doi-asserted-by":"crossref","first-page":"14105","DOI":"10.1073\/pnas.94.25.14105","volume":"94","author":"TA Grese","year":"1997","unstructured":"Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, Winter MA, Yang NN, Dodge JA: Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94: 14105\u201314110, 1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"247379_CR40","first-page":"230","volume":"10","author":"MM Montano","year":"1996","unstructured":"Montano MM, Ekena K, Krueger KD, Keller AL, Katzenellenbogen BS: Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 10: 230\u2013242, 1996","journal-title":"Mol Endocrinol"},{"key":"247379_CR41","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1073\/pnas.92.10.4206","volume":"92","author":"A Mahfoudi","year":"1995","unstructured":"Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W: Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92: 4206\u20134210, 1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"247379_CR42","first-page":"1872","volume":"58","author":"AS Levenson","year":"1999","unstructured":"Levenson AS, Jordan VC: The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 58: 1872\u20131875, 1999","journal-title":"Cancer Res"},{"key":"247379_CR43","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1126\/science.8197458","volume":"264","author":"S Halachmi","year":"1994","unstructured":"Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M: Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription. Science 264: 1455\u20131458, 1994","journal-title":"Science"},{"key":"247379_CR44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1006\/bbrc.1997.7522","volume":"239","author":"CL Yu","year":"1997","unstructured":"Yu CL, Driggers P, Barrera-Hernandez G, Nunez SB, Segars JH, Cheng SY: The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem Biophys Res Commun 239: 617\u2013620, 1997","journal-title":"Biochem Biophys Res Commun"},{"key":"247379_CR45","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/MCB.17.5.2735","volume":"17","author":"H Hong","year":"1997","unstructured":"Hong H, Kohli K, Garabedian MJ, Stallcup MR: GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 17: 2735\u20132744, 1997","journal-title":"Mol Cell Biol"},{"key":"247379_CR46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1210\/mend.11.6.0009","volume":"11","author":"CL Smith","year":"1997","unstructured":"Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist\/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen, Mol Endocrinoi 11: 657\u2013666, 1997","journal-title":"Mol Endocrinoi"},{"key":"247379_CR47","first-page":"45","volume":"63","author":"MG Parker","year":"1998","unstructured":"Parker MG: Transcriptional activation by oestrogen receptors. Biochem Soc Symp 63: 45\u201350, 1998","journal-title":"Biochem Soc Symp"},{"key":"247379_CR48","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1126\/science.277.5328.965","volume":"277","author":"SL Anzick","year":"1997","unstructured":"Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS: AIB1, a steroid receptor coactivator anplified in breast and ovarian cancer. Science 277: 965\u2013968, 1997","journal-title":"Science"},{"key":"247379_CR49","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1074\/jbc.273.20.12101","volume":"273","author":"SA Onate","year":"1998","unstructured":"Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai MJ, Edwards DP, O'Malley BW: The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation functionn 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem 273: 12101\u201312108, 1998","journal-title":"J Biol Chem"},{"key":"247379_CR50","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/mend.11.6.0004","volume":"11","author":"TA Jackson","year":"1997","unstructured":"Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB: The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domainbinding coactivator L7\/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11: 693\u2013705, 1997","journal-title":"Mol Endocrinol"},{"key":"247379_CR51","first-page":"159","volume":"395","author":"BS Hulka","year":"1996","unstructured":"Hulka BS: Epidemiology of susceptibility to breast cancer. Prog Clin Biol Res 395: 159\u2013174, 1996","journal-title":"Prog Clin Biol Res"},{"key":"247379_CR52","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.1984.2.10.1102","volume":"2","author":"GM Clark","year":"1984","unstructured":"Clark GM, Osborne CK, McGuire WL: Correlation between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2: 1102\u20131109, 1984","journal-title":"J Clin Oncol"},{"key":"247379_CR53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","volume":"2","author":"GT Beatson","year":"1896","unstructured":"Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2: 104\u2013107, 1896","journal-title":"Lancet"},{"key":"247379_CR54","first-page":"147","volume-title":"Breast Cancer Early and Late","author":"PE Robin","year":"1977","unstructured":"Robin PE, Dalton GA: The role of major endocrine ablation, In: Stoll BA (ed) Breast Cancer Early and Late. Yearbook Medical Publishers, Chicago, 1977, pp 147\u2013156"},{"key":"247379_CR55","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1995.13.2.513","volume":"13","author":"IA Jaiyesimi","year":"1995","unstructured":"Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN: Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 13: 513\u2013529, 1995","journal-title":"J Clin Oncol"},{"key":"247379_CR56","first-page":"3998","volume":"43","author":"RL Sutherland","year":"1983","unstructured":"Sutherland RL, Hall RE, Taylor JW: Cell proliferation kinetics of MCF7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res 43: 3998\u20134006, 1983","journal-title":"Cancer Res"},{"key":"247379_CR57","first-page":"3583","volume":"43","author":"CK Osborne","year":"1983","unstructured":"Osborne CK, Boldt DH, Clark GM, Trent JM: Effects of tamoxifen on human breast cancer cell kinetics: accumulation of cells in early G1 phase. Cancer Res 43: 3583\u20133585, 1983","journal-title":"Cancer Res"},{"key":"247379_CR58","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0753-3322(89)90084-X","volume":"43","author":"DS Saloman","year":"1989","unstructured":"Saloman DS, Ciardiello F, Valverius E, Saeki T, Kim N: Transforming growth factors in human breast cancer. Biomed Pharmacother 43: 661\u2013667, 1989","journal-title":"Biomed Pharmacother"},{"key":"247379_CR59","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/bjc.1995.527","volume":"72","author":"RR Perry","year":"1995","unstructured":"Perry RR, Kang Y, Greaves BR: Relationship between tamoxifen-induced transforming growth factor b1 expression cytostasis and apoptosis in human breast cancer cells. Br J Cancer 72: 1441\u20131446, 1995","journal-title":"Br J Cancer"},{"key":"247379_CR60","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0092-8674(87)90193-0","volume":"48","author":"C Knabbe","year":"1987","unstructured":"Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417\u2013428, 1987","journal-title":"Cell"},{"key":"247379_CR61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0303-7207(93)90217-8","volume":"97","author":"MH Jeng","year":"1993","unstructured":"Jeng MH, Ten Dijke P, Iwata KK, Jordan VC: Regulation of the levels of three transforming growth factor mRNAs by estrogen and their effects on the proliferation of human breast cancer cells. Mol Cell Endocrinol 97: 115\u2013123, 1993","journal-title":"Mol Cell Endocrinol"},{"key":"247379_CR62","first-page":"2606","volume":"57","author":"MA Guvakova","year":"1997","unstructured":"Guvakova MA, Surmacz E: Tamoxifen interferes with the insulin-like growth factor 1 receptor (IGF-1R) signaling pathway in breast cancer cells. Cancer Res 57: 2606\u20132610, 1997","journal-title":"Cancer Res"},{"key":"247379_CR63","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0959-8049(05)80045-0","volume":"28","author":"S Antoniotti","year":"1992","unstructured":"Antoniotti S, Maggiora P, Dati C, De Bortoli M: Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 28: 318\u2013321, 1992","journal-title":"Eur J Cancer"},{"key":"247379_CR64","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1210\/endo.137.3.8603578","volume":"137","author":"D Kleinman","year":"1996","unstructured":"Kleinman D, Karas M, Danilenko M, Arbeli A, Roberts CT, Jr., LeRoith D, Levy J, Sharoni Y: Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor(IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 137: 1089\u20131095, 1996","journal-title":"Endocrinology"},{"key":"247379_CR65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0014-2964(76)90030-X","volume":"12","author":"VC Jordan","year":"1976","unstructured":"Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomas. Eur J Cancer 12: 419\u2013424, 1976","journal-title":"Eur J Cancer"},{"key":"247379_CR66","first-page":"4020","volume":"47","author":"MM Gottardis","year":"1987","unstructured":"Gottardis MM, Jordan VC: The antitumor action of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47: 4020\u20134024, 1987","journal-title":"Cancer Res"},{"key":"247379_CR67","first-page":"5585","volume":"53","author":"HT Huynh","year":"1993","unstructured":"Huynh HT, Pollak M: Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53: 5585\u20135588, 1993","journal-title":"Cancer Res"},{"key":"247379_CR68","first-page":"3954","volume":"56","author":"SM Hyder","year":"1996","unstructured":"Hyder SM, Stancel GM, Chiappetta C, Murthy L, Boettger-Tong HL, Makela S: Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 56: 3954\u20133960, 1996","journal-title":"Cancer Res"},{"key":"247379_CR69","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/1097-0142(19930701)72:1<131::AID-CNCR2820720125>3.0.CO;2-Z","volume":"72","author":"S Noguchi","year":"1993","unstructured":"Noguchi S, Motomura K, Inaji Y Imaoka S, Koyama H: Down-regulation of transforming growth factor-a by tamoxifen in human breast cancer. Cancer 72: 131\u2013136, 1993","journal-title":"Cancer"},{"key":"247379_CR70","first-page":"4261","volume":"52","author":"A Butta","year":"1992","unstructured":"Butta A, MacLennan K, Flanders KC, Sacks NPM, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta AA: Induction of transforming growth factor b1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52: 4261\u20134264, 1992","journal-title":"Cancer Res"},{"key":"247379_CR71","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/1097-0142(19930215)71:4<1266::AID-CNCR2820710416>3.0.CO;2-K","volume":"71","author":"S Noguchi","year":"1993","unstructured":"Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H: Upregulation of estrogen receptor by tamoxifen in human breast cancer. Cancer 71: 1266\u20131272, 1993","journal-title":"Cancer"},{"key":"247379_CR72","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1005973529921","volume":"48","author":"A Makris","year":"1998","unstructured":"Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M: Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 48: 11\u201320, 1998","journal-title":"Breast Cancer Res Treat"},{"key":"247379_CR73","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0960-0760(92)90098-4","volume":"42","author":"CJ Newton","year":"1992","unstructured":"Newton CJ, Butta A, Nicholls J, Dowsett M: Oestradiol synthesis from oestrone in malignant breast epithelial cells: Studies on a high affinity, 80 kDa form of oestradiol dehydrogenase. J Steroid Biochem Mol Biol 42: 891\u2013900, 1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"247379_CR74","first-page":"741","volume":"64","author":"AE Wakeling","year":"1980","unstructured":"Wakeling AE, Slater SR: Estrogen-receptor binding and biologic activity of tamoxifen and its metabolites. Cancer Treat Rep 64: 741\u2013744, 1980","journal-title":"Cancer Treat Rep"},{"key":"247379_CR75","first-page":"127","volume":"25","author":"BS Furr","year":"1984","unstructured":"Furr BS, Jordan VC: The pharmacology and clinical uses of tamoxifen. Phannacol Ther 25: 127\u2013205, 1984","journal-title":"Phannacol Ther"},{"key":"247379_CR76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.1.5844.13","volume":"1","author":"HWC Ward","year":"1973","unstructured":"Ward HWC: Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1: 13\u201314, 1973","journal-title":"Br Med J"},{"key":"247379_CR77","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/0003-4819-87-6-687","volume":"87","author":"DT Kiang","year":"1977","unstructured":"Kiang DT, Kennedy BJ: Tamoxifen (antiestrogen) therapy in advanced breast cancer. Am Intern Med 87: 687\u2013690, 1977","journal-title":"Am Intern Med"},{"key":"247379_CR78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1005891506092","volume":"45","author":"M Gershanovich","year":"1997","unstructured":"Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmen J, Eastern European Study group: A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 45: 251\u2013262, 1997","journal-title":"Breast Cancer Res Treat"},{"key":"247379_CR79","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1005758127114","volume":"42","author":"JT Kuss","year":"1997","unstructured":"Kuss JT, Muss HB, Hoen H, Case LD: Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. Breast Cancer Res Treat 42: 265\u2013274, 1997","journal-title":"Breast Cancer Res Treat"},{"key":"247379_CR80","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1005903226483","volume":"48","author":"EMJJ Berns","year":"1998","unstructured":"Berns EMJJ, vanStaveren IL, Klijn JGM, Foekens JA: Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res Treat 48: 87\u201392, 1998","journal-title":"Breast Cancer Res Treat"},{"key":"247379_CR81","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.1997.15.5.1916","volume":"15","author":"RM Elledge","year":"1997","unstructured":"Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'sullivan J, Rivkin S, Martino S, Osborne CK: bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group Study. J Clin Oncol 15: 1916\u20131922, 1997","journal-title":"J Clin Oncol"},{"key":"247379_CR82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0304-3835(94)90194-5","volume":"81","author":"\u00c5 Borg","year":"1994","unstructured":"Borg \u00c5, Baldetorp B, Fern\u00f6 M, Killander D, Olsson H, Ryd\u00e9n S, Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81: 137\u2013144, 1994","journal-title":"Cancer Lett"},{"key":"247379_CR83","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/sj.bjc.6690196","volume":"79","author":"SJ Houston","year":"1999","unstructured":"Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220\u20131226, 1999","journal-title":"Br J Cancer"},{"key":"247379_CR84","first-page":"7","volume":"4","author":"DC Allred","year":"1998","unstructured":"Allred DC, Ciocca D, Clark GM, Elledge RM, Green S, Hill J, Martino S, O'sullivan J, Osborne CK, Pugh R, Ravdin P: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 4: 7\u201312, 1998","journal-title":"Clin Cancer Res"},{"key":"247379_CR85","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jnci\/87.10.751","volume":"87","author":"JA Foekens","year":"1995","unstructured":"Foekens JA, Look MP, Peters HA, Van Putten WLJ, Portengen H, Klijn JGM: Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recwrrent breast cancer. J Natl Cancer Inst 87: 751\u2013756, 1995","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR86","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/bjc.1994.476","volume":"70","author":"JA Foekens","year":"1994","unstructured":"Foekens JA, Portengen H, Look MP, Van Putten WLJ, Thirion B, Bontenbal M, Klijn JGM: Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 70: 1217\u20131223, 1994","journal-title":"Br J Cancer"},{"key":"247379_CR87","first-page":"1643","volume":"3","author":"JC Newby","year":"1997","unstructured":"Newby JC, Johnston SRD, Smith IE, Dowsett M: Expression of epidermal growth factor receptor and c-erbB-2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643\u20131651, 1997","journal-title":"Clin Cancer Res"},{"key":"247379_CR88","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1200\/JCO.1998.16.1.121","volume":"16","author":"EMJJ Berns","year":"1998","unstructured":"Berns EMJJ, Klijn JGM, Van Putten WLJ, de Witte HH, Look MP, van Gelder MEM, Willman K, Portengen HW, Benraad TJ, Foekens JA: p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Oncol 16: 121\u2013127, 1998","journal-title":"J Clin Oncol"},{"key":"247379_CR89","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/(SICI)1097-0215(19990219)84:1<54::AID-IJC11>3.0.CO;2-X","volume":"84","author":"JMW Gee","year":"1999","unstructured":"Gee JMW, Willsher PC, Kenny FS, Robertson JFR, Pinder SE, Ellis IO, Nicholson RI: Endocrine response and resistance in breast cancer: A role for the transcription factor Fos. Int J Cancer 84: 54\u201361, 1999","journal-title":"Int J Cancer"},{"key":"247379_CR90","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.1996.14.9.2584","volume":"14","author":"T Kuukasj\u00e4rvi","year":"1996","unstructured":"Kuukasj\u00e4rvi T, Kononen J, Helin H, Holli K, Isola J: Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14: 2584\u20132589, 1996","journal-title":"J Clin Oncol"},{"key":"247379_CR91","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists","year":"1998","unstructured":"Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451\u20131467, 1998","journal-title":"Lancet"},{"key":"247379_CR92","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","volume":"353","author":"B Fisher","year":"1999","unstructured":"Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353: 1993\u20132000, 1999","journal-title":"Lancet"},{"key":"247379_CR93","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, TanChiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90: 1371\u20131388, 1998","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR94","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","volume":"352","author":"T Powles","year":"1998","unstructured":"Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98\u2013101, 1998","journal-title":"Lancet"},{"key":"247379_CR95","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)04394-3","volume":"352","author":"U Veronesi","year":"1998","unstructured":"Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomized women. Lancet 352: 93\u201397, 1998","journal-title":"Lancet"},{"key":"247379_CR96","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/1097-0142(19840215)53:4<853::AID-CNCR2820530406>3.0.CO;2-M","volume":"53","author":"A Gotfredsen","year":"1984","unstructured":"Gotfredsen A, Christiansen C, Palshof T: The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 53: 853\u2013857, 1984","journal-title":"Cancer"},{"key":"247379_CR97","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0140-6736(98)85002-2","volume":"352","author":"KI Pritchard","year":"1998","unstructured":"Pritchard KI: Is tamoxifen effective in prevention of breast cancer? Lancet 352: 80\u201381, 1998","journal-title":"Lancet"},{"key":"247379_CR98","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y","volume":"80","author":"SE Karp","year":"1997","unstructured":"Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD: Innuence of BRCA1 mutations on nuc307 lear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80: 435\u2013441, 1997","journal-title":"Cancer"},{"key":"247379_CR99","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W","volume":"83","author":"N Loman","year":"1998","unstructured":"Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83: 310\u2013319, 1998","journal-title":"Cancer"},{"key":"247379_CR100","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/jnci\/83.20.1488","volume":"83","author":"VC Jordan","year":"1991","unstructured":"Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC: Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83: 1488\u20131491, 1991","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR101","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1677\/joe.0.0700421","volume":"70","author":"GV Groom","year":"1976","unstructured":"Groom GV, Griffiths K: Effects of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70: 421\u2013428, 1976","journal-title":"J Endocrinol"},{"key":"247379_CR102","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(97)24029-8","volume":"350","author":"K Tewari","year":"1997","unstructured":"Tewari K, Bonebrake RG, Asrat T, Shanberg AM: Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 350: 183\u2013183, 1997","journal-title":"Lancet"},{"key":"247379_CR103","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1006\/gyno.1998.5201","volume":"72","author":"I Cohen","year":"1999","unstructured":"Cohen I, Figer A, Tepper R, Shapira J, Altaras MM, Yigael D, Beyth Y: Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: Comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol Oncol 72: 202\u2013207, 1999","journal-title":"Gynecol Oncol"},{"key":"247379_CR104","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/sj.bjc.6690280","volume":"79","author":"MJE Mourits","year":"1999","unstructured":"Mourits MJE, Devries EGE, Willemse PHB, tenHoor KA, Hollema H, Sluiter WJ, Debruijn HWA, Vanderzee AGJ: Ovarian cysts in women receiving tamoxifen for breast cancer.Br J Cancer 79: 1761\u20131764, 1999","journal-title":"Br J Cancer"},{"key":"247379_CR105","first-page":"624","volume":"47","author":"VC Jordan","year":"1987","unstructured":"Jordan VC, Fritz NF, Tormey DC: Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 47: 624\u2013630, 1987","journal-title":"Cancer Res"},{"key":"247379_CR106","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0301-2115(98)00117-1","volume":"80","author":"M Friedrich","year":"1998","unstructured":"Friedrich M, Mink D, VillenaHeinsen C, Wollhermann A, Schmidt W: Tamoxifen and proliferation of vaginal and cervical epithelium in postmenopausal women with breast cancer. Eur J Obstet Gynecol Reprod Biol 80: 221\u2013225, 1998","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"247379_CR107","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF01833337","volume":"22","author":"MN Pollak","year":"1992","unstructured":"Pollak MN, Huynh HT, Lefebvre SP: Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 22: 91\u2013100, 1992","journal-title":"Breast Cancer Res Treat"},{"key":"247379_CR108","first-page":"4719","volume":"52","author":"PE Lonning","year":"1992","unstructured":"Lonning PE, Hall K, Aakvaag A, Lien EA: Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 52: 4719\u20134723, 1992","journal-title":"Cancer Res"},{"key":"247379_CR109","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","volume":"326","author":"RR Love","year":"1992","unstructured":"Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852\u2013856, 1992","journal-title":"N Engl J Med"},{"key":"247379_CR110","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.1994.12.5.992","volume":"12","author":"B Kristensen","year":"1994","unstructured":"Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbol I, Mouridsen HT: Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study. J Clin Oncol 12: 992\u2013997, 1994","journal-title":"J Clin Oncol"},{"key":"247379_CR111","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","volume":"14","author":"TJ Powles","year":"1996","unstructured":"Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S: Effect of tamoxifen on bone mineral density measured by dualenergy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14: 78\u201384, 1996","journal-title":"J Clin Oncol"},{"key":"247379_CR112","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/86.20.1534","volume":"86","author":"RR Love","year":"1995","unstructured":"Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86: 1534\u20131539, 1995","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR113","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/01.CIR.75.6.1102","volume":"75","author":"TL Bush","year":"1987","unstructured":"Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM: Cardiovascular mortality and noncontraceptive use of estrogens in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 75: 1102\u20131109, 1987","journal-title":"Circulation"},{"key":"247379_CR114","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/jnci\/85.17.1398","volume":"85","author":"LE Rutquist","year":"1993","unstructured":"Rutquist LE, Matteson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of tamoxifen: the Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85: 1398\u20131406, 1993","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR115","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/jcem-70-4-1132","volume":"70","author":"JD Bagdade","year":"1990","unstructured":"Bagdade JD, Wolter J, Subbaiah PV, Ryan W: Effects of tamoxifen treatment on plasma lipids and lipoprotein composition. J Clin Endocrinol Metab 70: 1132\u20131135, 1990","journal-title":"J Clin Endocrinol Metab"},{"key":"247379_CR116","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0021-9150(84)90064-9","volume":"53","author":"S Rossner","year":"1984","unstructured":"Rossner S, Wallgren A: Serum lipoprotein and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 53: 339\u2013346, 1984","journal-title":"Atherosclerosis"},{"key":"247379_CR117","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/jnci\/89.11.776","volume":"89","author":"JP Costantino","year":"1997","unstructured":"Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89: 776\u2013782, 1997","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR118","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0140-6736(92)90997-H","volume":"339","author":"Early Breast Cancer Trialists","year":"1992","unstructured":"Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 71\u201385, 1992","journal-title":"Lancet"},{"key":"247379_CR119","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/bmj.316.7139.1181","volume":"316","author":"P Bruzzi","year":"1998","unstructured":"Bruzzi P: Tamoxifen for the prevention of breast cancer -important questions remain unanswered, and existing trials should continue. Br Med J 316: 1181\u20131182, 1998","journal-title":"Br Med J"},{"key":"247379_CR120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM199408113310602","volume":"331","author":"CL Loprinzi","year":"1994","unstructured":"Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE, Bate WW, Rospond RM, Oesterling JE: Megestrol acetate for the prevention of hot flashes. N Engl J Med 331: 347\u2013352, 1994","journal-title":"N Engl J Med"},{"key":"247379_CR121","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.1998.16.2.495","volume":"16","author":"DL Barton","year":"1998","unstructured":"Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, Fidler P, Stella PJ, Swan DK, Vaught NL, Novotny P: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16: 495\u2013500, 1998","journal-title":"J Clin Oncol"},{"key":"247379_CR122","first-page":"1360","volume":"52","author":"X Han","year":"1992","unstructured":"Han X, Liehr JG: Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360\u20131363, 1992","journal-title":"Cancer Res"},{"key":"247379_CR123","first-page":"4374","volume":"56","author":"K Hemminki","year":"1996","unstructured":"Hemminki K, Rajaniemi H, Lindahl B, Moberger B: Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res 56: 4374\u20134377, 1996","journal-title":"Cancer Res"},{"key":"247379_CR124","first-page":"1438","volume":"57","author":"DH Li","year":"1997","unstructured":"Li DH, Dragan Y, Jordan VC, Wang MY, Pitot HC: Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res 57: 1438\u20131441, 1997","journal-title":"Cancer Res"},{"key":"247379_CR125","first-page":"2091","volume":"59","author":"I Terashima","year":"1999","unstructured":"Terashima I, Suzuki N, Shibutani S: Mutagenic potential of a-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res 59: 2091\u20132095, 1999","journal-title":"Cancer Res"},{"key":"247379_CR126","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1993.11.3.485","volume":"11","author":"U Magriples","year":"1993","unstructured":"Magriples U, Naftolin F, Schwartz PE, Carcangiu ML: Highgrade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11: 485\u2013490, 1993","journal-title":"J Clin Oncol"},{"key":"247379_CR127","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/S0140-6736(94)92466-X","volume":"343","author":"RP Kedar","year":"1994","unstructured":"Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343: 1318\u20131321, 1994","journal-title":"Lancet"},{"key":"247379_CR128","first-page":"S1-55","volume":"24","author":"CJ Cohen","year":"1997","unstructured":"Cohen CJ: Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. Semin Oncol 24: S1-55\u2013S1-64, 1997","journal-title":"Semin Oncol"},{"key":"247379_CR129","first-page":"660","volume":"81","author":"E Lahti","year":"1993","unstructured":"Lahti E, Bianco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T: Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81: 660\u2013664, 1993","journal-title":"Obstet Gynecol"},{"key":"247379_CR130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1074-3804(05)80224-5","volume":"4","author":"D Marconi","year":"1997","unstructured":"Marconi D, Exacoustos C, Cangi B, Perroni A, Zupi E, Valli E, Romanini C: Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen. J Am Assoc Gynecol Laparosc 4: 331\u2013339, 1997","journal-title":"J Am Assoc Gynecol Laparosc"},{"key":"247379_CR131","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/gyno.1997.4739","volume":"66","author":"WF Cheng","year":"1997","unstructured":"Cheng WF, Lin HH, Torng PL, Huang SC: Comparison of endometrial changes among symptomatic tamoxifen-treated 308 and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 66: 233\u2013237, 1997","journal-title":"Gynecol Oncol"},{"key":"247379_CR132","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1006\/gyno.1996.4568","volume":"64","author":"R Tepper","year":"1997","unstructured":"Tepper R, Beyth Y, Altaras MM, Zalel Y, Shapira J, Cordoba M, Cohen I: Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol 64: 386\u2013391, 1997","journal-title":"Gynecol Oncol"},{"key":"247379_CR133","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJM199712183372502","volume":"337","author":"RD Langer","year":"1997","unstructured":"Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabal JF, Barnabei VM, Merino MJ, Scully RE: Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 337: 1792\u20131798, 1997","journal-title":"N Engl J Med"},{"key":"247379_CR134","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0002-9378(98)70315-1","volume":"178","author":"KF McGonigle","year":"1998","unstructured":"McGonigle KF, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson JF: Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 178: 1145\u20131150, 1998","journal-title":"Am J Obstet Gynecol"},{"key":"247379_CR135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1005820115535","volume":"47","author":"G Bertelli","year":"1998","unstructured":"Bertelli G, Cosso M, Cusimano E, Delmastro L, Garrone O, Guide T, Gustavino C, Nicolo G, Rosso A, Venturini M: Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 47: 41\u201346, 1998","journal-title":"Breast Cancer Res Treat"},{"key":"247379_CR136","first-page":"625","volume":"18","author":"S Fotiou","year":"1998","unstructured":"Fotiou S, Tserkezoglou A, Hadjieleftheriou G, Apostolikas N, Karydas I, Stravolemos K: Tamoxifen associated uterine pathology in breast cancer patients with abnormal bleeding. Anticancer Res 18: 625\u2013630, 1998","journal-title":"Anticancer Res"},{"key":"247379_CR137","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(78)91668-9","volume":"2","author":"K Nevassari","year":"1978","unstructured":"Nevassari K, Heikkinein U, Taskinen PJ: Tamoxifen and thrombosis. Lancet 2: 946\u2013947, 1978","journal-title":"Lancet"},{"key":"247379_CR138","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jama.1980.03300320012005","volume":"243","author":"A Hendrick","year":"1980","unstructured":"Hendrick A, Sebramanian VP: Tamoxifen and thromboembolism. JAMA 243: 514\u2013515, 1980","journal-title":"JAMA"},{"key":"247379_CR139","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.1991.9.10.1740","volume":"9","author":"T Fornander","year":"1991","unstructured":"Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Rotstein S, Hjalmar M-L, Perbeck L: Adjuvant tamoxifen in early-stage breast cancer: Effects on intercurrent morbidity and mortality. J Clin Oncol 9: 1740\u20131748, 1991","journal-title":"J Clin Oncol"},{"key":"247379_CR140","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF00665973","volume":"30","author":"CC Mamby","year":"1994","unstructured":"Mamby CC, Love RR, Feyzi JM: Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women. Breast Cancer Res Treat 30: 311\u2013314, 1994","journal-title":"Breast Cancer Res Treat"},{"key":"247379_CR141","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/1097-0142(19840615)53:12<2607::AID-CNCR2820531206>3.0.CO;2-T","volume":"53","author":"RE Enck","year":"1984","unstructured":"Enck RE, Rios CM; Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53: 2607\u20132609, 1984","journal-title":"Cancer"},{"key":"247379_CR142","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/1097-0142(19880401)61:7<1316::AID-CNCR2820610707>3.0.CO;2-5","volume":"61","author":"MJ Auger","year":"1988","unstructured":"Auger MJ, Mackle MJ: Effects of tamoxifen in blood coagulation. Cancer 61: 1316\u20131319, 1988","journal-title":"Cancer"},{"key":"247379_CR143","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1200\/JCO.1996.14.3.1018","volume":"14","author":"SG Mayfield","year":"1996","unstructured":"Mayfield SG, Gorin MB: Tamoxifen-associated eye disease: a review. J Clin Oncol 14: 1018\u20131026, 1996","journal-title":"J Clin Oncol"},{"key":"247379_CR144","first-page":"5183","volume":"48","author":"MM Gottardis","year":"1988","unstructured":"Gottardis MM, Jordan VC: Development of tamoxifenstimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183\u20135187, 1988","journal-title":"Cancer Res"},{"key":"247379_CR145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(87)90717-3","volume":"1","author":"PA Canney","year":"1987","unstructured":"Canney PA, Griffiths T, Latief TN, Priestman TJ: Clinical significance of tamoxifen withdrawal response. Lancet 1: 36, 1987","journal-title":"Lancet"},{"key":"247379_CR146","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","volume":"88","author":"B Fisher","year":"1996","unstructured":"Fisher B, Dignam J, Bryant J, Decillis A, Wickerham DL, Wolmark N, Constantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evens J, Lickley HL: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529\u20131542, 1996","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR147","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/0959-8049(93)90218-5","volume":"29A","author":"LR Wiseman","year":"1993","unstructured":"Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FEB, Westley BR: Type I ICF receptor and acquired tamoxifen resistance in oestrogen-repponsive human breast cancer cells. Eur J Cancer 29A: 2256\u20132264, 1993","journal-title":"Eur J Cancer"},{"key":"247379_CR148","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF00665801","volume":"26","author":"CA Encarnaci\u00f3n","year":"1993","unstructured":"Encarnaci\u00f3n CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SAW, Osborne CK: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26: 237\u2013246, 1993","journal-title":"Breast Cancer Res Treat"},{"key":"247379_CR149","first-page":"3331","volume":"55","author":"SRD Johnston","year":"1495","unstructured":"Johnston SRD, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55: 3331\u20133338, 1495","journal-title":"Cancer Res"},{"key":"247379_CR150","doi-asserted-by":"crossref","first-page":"14897","DOI":"10.1021\/bi971746l","volume":"36","author":"KE Carlson","year":"1997","unstructured":"Carlson KE, Choi I, Gee A, Katzenellenbogen BS, Katzenellenbogen JA: Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36: 14897\u201314905, 1997","journal-title":"Biochemistry"},{"key":"247379_CR151","first-page":"877","volume":"58","author":"GB Tremblay","year":"1998","unstructured":"Tremblay GB, Tremblay A, Labrie F, Giguere V: Ligandindependent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res 58: 877\u2013881, 1998","journal-title":"Cancer Res"},{"key":"247379_CR152","first-page":"349","volume":"54","author":"PS Karnik","year":"1994","unstructured":"Karnik PS, Kulkami S, Liu X-P, Budd GT, Bukowski RM: Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 54: 349\u2013353, 1994","journal-title":"Cancer Res"},{"key":"247379_CR153","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF00689688","volume":"26","author":"LC Murphy","year":"1993","unstructured":"Murphy LC, Dotzlaw H, Hamerton J, Schwarz J: Investigation of the origin of variant, truncated estrogen receptorlike mRNAs identified in some human breast cancer biopsy samples. Breast Cancer Res Treat 26: 149\u2013161, 1993","journal-title":"Breast Cancer Res Treat"},{"key":"247379_CR154","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0960-0760(98)00012-0","volume":"65","author":"LC Murphy","year":"1998","unstructured":"Murphy LC, Dotzlaw H, Leygue E, Coutts A, Watson P: The pathophysiological role of estrogen receptor variants in human breast cancer. J Steroid Biochem Mol Biol 65: 175\u2013180, 1998","journal-title":"J Steroid Biochem Mol Biol"},{"key":"247379_CR155","first-page":"105","volume":"51","author":"SAW Fuqua","year":"1991","unstructured":"Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O'Malley BW, McGuire WL: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51: 105\u2013109, 1991","journal-title":"Cancer Res"},{"key":"247379_CR156","first-page":"5934","volume":"53","author":"CG Castles","year":"1993","unstructured":"Castles CG, Fuqua SAW, Klotz DM, Hill SM: Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res 53: 5934\u20135939, 1993","journal-title":"Cancer Res"},{"key":"247379_CR157","first-page":"483","volume":"52","author":"SAW Fuqua","year":"1992","unstructured":"Fuqua SAW, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL: Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52: 483\u2013486, 1992","journal-title":"Cancer Res"},{"key":"247379_CR158","first-page":"4324","volume":"56","author":"E Leygue","year":"1996","unstructured":"Leygue E, Huang AH Murphy LC, Watson PH: Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res 56: 4324\u20134327, 1996","journal-title":"Cancer Res"},{"key":"247379_CR159","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0960-0760(96)00120-3","volume":"59","author":"QX Zhang","year":"1996","unstructured":"Zhang QX, Hilsenbeck SG, Fuqua SAW, Borg A: Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol 59: 251\u2013260, 1996","journal-title":"J Steroid Biochem Mol Biol"},{"key":"247379_CR160","first-page":"288","volume":"55","author":"AAI Daffada","year":"1995","unstructured":"Daffada AAI, Johnston SRD, Smith EE, Detre S, King N, Dowsett M: Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor\/pS2 status in human breast cancer. Cancer Res 55: 288\u2013293, 1995","journal-title":"Cancer Res"},{"key":"247379_CR161","first-page":"182","volume":"8","author":"H Lahooti","year":"1994","unstructured":"Lahooti H, White R, Danielian PS, Parker MG: Characterization of ligand-dependent phosphorylation of the estrogen receptor. Mol Endocrinol 8: 182\u2013188, 1994","journal-title":"Mol Endocrinol"},{"key":"247379_CR162","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1210\/endo.136.3.7867590","volume":"136","author":"ME Astruc","year":"1995","unstructured":"Astruc ME, Chabret C, Bali P, Gagne D, Pens M: Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: Involvement of the estrogen receptor. Endocrinology 136: 824\u2013832, 1995","journal-title":"Endocrinology"},{"key":"247379_CR163","first-page":"351","volume":"7","author":"JA Dumont","year":"1996","unstructured":"Dumont JA, Bitoni AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE: Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 7: 351\u2013359, 1996","journal-title":"Cell Growth Differ"},{"key":"247379_CR164","first-page":"251","volume":"5","author":"SRD Johnston","year":"1999","unstructured":"Johnston SRD, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5: 251\u2013256, 1999","journal-title":"Clin Cancer Res"},{"key":"247379_CR165","first-page":"3723","volume":"57","author":"SRD Johnston","year":"1997","unstructured":"Johnston SRD, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC: Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogenresistant human breast tumors. Cancer Res 57: 3723\u20133727, 1997","journal-title":"Cancer Res"},{"key":"247379_CR166","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/jnci\/83.20.1477","volume":"83","author":"CK Osborne","year":"1991","unstructured":"Osborne CK, Coronado E, Alfred DC, Wiebe V, DeGregorio M: Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83: 1477\u20131482, 1991","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR167","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1992.10.2.304","volume":"10","author":"CK Osborne","year":"1992","unstructured":"Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW: Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10: 304\u2013310, 1992","journal-title":"J Clin Oncol"},{"key":"247379_CR168","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1200\/JCO.1992.10.6.990","volume":"10","author":"VJ Wiebe","year":"1992","unstructured":"Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW: Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10: 990\u2013994, 1992","journal-title":"J Clin Oncol"},{"key":"247379_CR169","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/jnci\/85.10.806","volume":"85","author":"DM Wolf","year":"1993","unstructured":"Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC: Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 85: 806\u2013812, 1993","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF00685924","volume":"34","author":"CK Osborne","year":"1984","unstructured":"Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE: The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34: 89\u201395, 1984","journal-title":"Cancer Chemother Pharmacol"},{"key":"247379_CR171","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0277-5379(90)90191-U","volume":"26","author":"SM Langan-Fahey","year":"1990","unstructured":"Langan-Fahey SM, Tormey DC, Jordan VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26: 883\u2013888, 1990","journal-title":"Eur J Cancer"},{"key":"247379_CR172","first-page":"870","volume":"7","author":"LCJ Dorssers","year":"1993","unstructured":"Dorssers LCJ, van Agthoven T, Dekker A, Van Agthoven TLA, Kok EM: Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: Identification of bcar-1, a common integration site. Mol Endocrinol 7: 870\u2013878, 1993","journal-title":"Mol Endocrinol"},{"key":"247379_CR173","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/emboj\/17.10.2799","volume":"17","author":"T van Agthoven","year":"1998","unstructured":"van Agthoven T, Van Agthoven TLA, Dekker A, van der Spek PJ, Vreede L, Dorssers LCJ: Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17: 2799\u20132808, 1998","journal-title":"EMBO J"},{"key":"247379_CR174","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.1997.15.2.840","volume":"15","author":"WJ Gradishar","year":"1997","unstructured":"Gradishar WJ, Jordan VC: Clinical potential of new antiestrogens. J Clin Oncol 15: 840\u2013852, 1997","journal-title":"J Clin Oncol"},{"key":"247379_CR175","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/jnci\/90.10.729","volume":"90","author":"C McNeil","year":"1998","unstructured":"McNeil C: In search of the perfect SERM: Beyond tamoxifen and raloxifene. J Natl Cancer Inst 90: 956\u2013957, 1998","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR176","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF00306737","volume":"17","author":"L Kangas","year":"1986","unstructured":"Kangas L, Neiminen A-L, Bianco G, Gronroos M, Kattio S, Karjalainen A, Perilla M, Sodervall M, Tiovola R: A new triphenylethylene compound Fc-1157A. II antitumor effects. Cancer Chemother Pharmacol 17: 109\u2013113, 1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"247379_CR177","first-page":"4534","volume":"53","author":"GC Hard","year":"1993","unstructured":"Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM: Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD (BR) rats. Cancer Res 53: 4534\u20134541, 1993","journal-title":"Cancer Res"},{"key":"247379_CR178","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1997.375","volume":"76","author":"S Pyrhonen","year":"1997","unstructured":"Pyrhonen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, Bauer J, Westman G, Lundgren S, Bianco G, Mella O, Nilsson I, Hietanen T, Hindy I, Vuorinen J, Hajba A: Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized doubleblind, the \"nordic\" phase III study. Br J Cancer 76: 270\u2013277, 1997","journal-title":"Br J Cancer"},{"key":"247379_CR179","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.1995.13.10.2556","volume":"13","author":"DF Hayes","year":"1995","unstructured":"Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Schoenfelder J: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556\u20132566, 1995","journal-title":"J Clin Oncol"},{"key":"247379_CR180","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.1993.11.2.345","volume":"11","author":"CL Vogel","year":"1993","unstructured":"Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR: Multicenter phase II efficacy trial of toremifene in tamoxifenrefractory patients with advanced breast cancer. J Clin Oncol 11: 345\u2013350, 1993","journal-title":"J Clin Oncol"},{"key":"247379_CR181","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/jnci\/90.20.1552","volume":"90","author":"RM O'Regan","year":"1998","unstructured":"O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenznar HD, Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pitot HC, Chatterton R, Jordan VC: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 90: 1552\u20131558, 1998","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR182","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/gyno.1995.0019","volume":"59","author":"E Tomas","year":"1995","unstructured":"Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T: Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 59: 241\u2013266, 1995","journal-title":"Gynecol Oncol"},{"key":"247379_CR183","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0960-0760(98)00011-9","volume":"65","author":"DA Tonetti","year":"1998","unstructured":"Tonetti DA, O'Regan R, Tanjore S, England G, Jordan VC: Antiestrogen stimulated human endometrial cancer growth: Laboratory and clinical considerations. J Steroid Biochem Mol Biol 65: 181\u2013189, 1998","journal-title":"J Steroid Biochem Mol Biol"},{"key":"247379_CR184","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1210\/jcem.83.4.4688","volume":"83","author":"MB Marttunen","year":"1998","unstructured":"Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O: Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83: 1158\u20131162, 1998","journal-title":"J Clin Endocrinol Metab"},{"key":"247379_CR185","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/JCO.1998.16.1.348","volume":"16","author":"AU Buzdar","year":"1998","unstructured":"Buzdar AU, Hortobagyi GN: Tamoxifen and tamoxifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 16: 348\u2013353, 1998","journal-title":"J Clin Oncol"},{"key":"247379_CR186","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0304-3835(94)90364-6","volume":"84","author":"M Hasmann","year":"1994","unstructured":"Hasmann M, Rattel B, Loser R: Preclinical data for droloxifene. Cancer Lett 84: 101\u2013116, 1994","journal-title":"Cancer Lett"},{"key":"247379_CR187","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF00689679","volume":"31","author":"W Rauschning","year":"1994","unstructured":"Rauschning W, Pritchard KI: Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Res Treat 31: 83\u201394, 1994","journal-title":"Breast Cancer Res Treat"},{"key":"247379_CR188","first-page":"5851","volume":"51","author":"SK Chander","year":"1991","unstructured":"Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC: Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res 51: 5851\u20135858, 1991","journal-title":"Cancer Res"},{"key":"247379_CR189","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/bjc.1997.449","volume":"76","author":"P Pace","year":"1997","unstructured":"Pace P, Jarman M, Phillips D, Hewer A, Bliss J, Coombes RC: Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts. Br J Cancer 76: 700\u2013704, 1997","journal-title":"Br J Cancer"},{"key":"247379_CR190","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/bjc.1997.144","volume":"75","author":"SRD Johnston","year":"1997","unstructured":"Johnston SRD, Riddler S, Haynes BP, A'Hern R, Smith IE, Jarman M, Dowsett M: The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. Br J Cancer 75: 804\u2013809, 1997","journal-title":"Br J Cancer"},{"key":"247379_CR191","first-page":"1070","volume":"55","author":"RC Coombes","year":"1995","unstructured":"Coombes RC, Haynes BP, Dowsett M, Quigley M, English J, Judson IR, Griggs LJ, Potter GA, McCague R, Jarman M: Idoxifene: Report of a phase I study in patients with metastatic breast cancer. Cancer Res 55: 1070\u20131074, 1995","journal-title":"Cancer Res"},{"key":"247379_CR192","first-page":"3229","volume":"53","author":"N Br\u00fcnner","year":"1993","unstructured":"Br\u00fcnner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R: MCF7\/LCC2: 310 A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53: 3229\u20133232, 1993","journal-title":"Cancer Res"},{"key":"247379_CR193","first-page":"4090","volume":"49","author":"MM Gottardis","year":"1989","unstructured":"Gottardis MM, Jiang SY, Jeng MH, Jordan VC: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49: 4090\u20134093, 1989","journal-title":"Cancer Res"},{"key":"247379_CR194","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/jnci\/87.10.746","volume":"87","author":"CK Osborne","year":"1995","unstructured":"Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, Mc-Cue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87: 746\u2013750, 1995","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR195","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<299::AID-IJC21>3.0.CO;2-8","volume":"81","author":"M Salerno","year":"1999","unstructured":"Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S, Surmacz E: Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer 81: 299\u2013304, 1999","journal-title":"Int J Cancer"},{"key":"247379_CR196","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/bjc.1996.357","volume":"74","author":"A Howell","year":"1996","unstructured":"Howell A, DeFriend DJ, Robertson JFR, Blamey RW, Anderson L, Anderson E, Sutcliffe FA, Walton P: Pharmacokinetics, pharmacological and anti-tumour effects of the specific antioestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 74: 300\u2013308, 1996","journal-title":"Br J Cancer"},{"key":"247379_CR197","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1210\/endo.139.9.6172","volume":"139","author":"JD Sibonga","year":"1998","unstructured":"Sibonga JD, Dobnig H, Harden RM, Turner RT: Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 139: 3736\u20133742, 1998","journal-title":"Endocrinology"},{"key":"247379_CR198","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/0024-3205(83)90323-5","volume":"32","author":"JA Clemens","year":"1983","unstructured":"Clemens JA, Bennett DR, Black LJ, Jones CD: Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 32: 2875, 1983","journal-title":"Life Sci"},{"key":"247379_CR199","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000226637","volume":"45","author":"AU Buzdar","year":"1988","unstructured":"Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G: Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45: 344\u2013345, 1988","journal-title":"Oncology"},{"key":"247379_CR200","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1172\/JCI116985","volume":"93","author":"LJ Black","year":"1994","unstructured":"Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU: Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93: 63\u201369, 1994","journal-title":"J Clin Invest"},{"key":"247379_CR201","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","volume":"337","author":"PD Delmas","year":"1997","unstructured":"Delmas PD, Bjarnson NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641\u20131647, 1997","journal-title":"N Engl J Med"},{"key":"247379_CR202","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"SR Cummings","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women -Results from the MORE trial. JAMA 281: 2189\u20132197, 1999","journal-title":"JAMA"},{"key":"247379_CR203","unstructured":"Cummings SR, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R, Black DM, Nickelsen T, Glusman J, Krueger K: Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Proc Am Soc Clin Oncol 17: 2a(Abstract), 1998"},{"key":"247379_CR204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(24)37755-9","volume":"287","author":"M Sato","year":"1998","unstructured":"Sato M, Turner CH, Wang TY, Adrian MD, Rowley E, Bryant HU: LY353381.HCl: A novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Therapeutics 287: 1\u20137, 1998","journal-title":"J Pharmacol Exp Therapeutics"},{"key":"247379_CR205","first-page":"3538","volume":"38","author":"M Sporn","year":"1997","unstructured":"Sporn M, Suh N, Peer C, Williams C, Roebuck B, Glasebrook A, Palkowitz A, Bryant M, Sato M, Yang N, Fuchs-Young R: LY353381.HCl, a new benzothiophene for chemoprevention of breast cancer (Abstract). Proc Am Assoc Cancer Res 38: 3538, 1997","journal-title":"Proc Am Assoc Cancer Res"},{"key":"247379_CR206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1005928814521","volume":"49","author":"SQ Luo","year":"1998","unstructured":"Luo SQ, Labrie C, Belanger A, Candas B, Labrie F: Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050). Breast Cancer Res Treat 49: 1\u201311, 1998","journal-title":"Breast Cancer Res Treat"},{"key":"247379_CR207","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<104::AID-IJC16>3.0.CO;2-G","volume":"73","author":"J Simard","year":"1997","unstructured":"Simard J, Labrie C, Belanger A, Gauthier S, Singh SM, Merand Y, Labrie F: Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogeninduced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int J Cancer 73: 104\u2013112, 1997","journal-title":"Int J Cancer"},{"key":"247379_CR208","first-page":"60","volume":"58","author":"S Couillard","year":"1998","unstructured":"Couillard S, Gutman M, Labrie C, Belanger A, Candas B, Labrie F: Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res 58: 60\u201364, 1998","journal-title":"Cancer Res"},{"key":"247379_CR209","doi-asserted-by":"crossref","first-page":"5605","DOI":"10.1210\/endo.138.12.5560","volume":"138","author":"A Sourla","year":"1997","unstructured":"Sourla A, Luo S, Labrie C, Belanger A, Labrie F: Morphological changes induced by 6-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. Endocrinology 138: 5605\u20135617, 1997","journal-title":"Endocrinology"},{"key":"247379_CR210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/(SICI)1097-0215(19971104)73:3<381::AID-IJC13>3.0.CO;2-G","volume":"73","author":"S Luo","year":"1997","unstructured":"Luo S, Martel C, Sourla A, Gauthier S, Merand Y, Belanger A, Labrie C, Labrie F: Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice. Int J Cancer 73: 381\u2013391, 1997","journal-title":"Int J Cancer"},{"key":"247379_CR211","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1210\/endo.139.1.5702","volume":"139","author":"A Tremblay","year":"1998","unstructured":"Tremblay A, Tremblay GB, Labrie C, Labrie F, Giguere V: EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors a and b. Endocrinology 139: 111\u2013118, 1998","journal-title":"Endocrinology"},{"key":"247379_CR212","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1021\/jm980048b","volume":"41","author":"RL Rosati","year":"1998","unstructured":"Rosati RL, Jardine PD, Cameron KO, Thompson DD, Ke HZ, Toler SM, Brown TA, Pan LC, Ebbinghaus CF, Reinhold AR, Elliott NC, Newhouse BN, Tjoa CM, Sweetnam PM, Cole MJ, Arriola MW, Gauthier JW, Crawford DT, Nickerson DF, Pirie CM, Qi H, Simmons HA, Tkalcevic GT: Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist\/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 41: 2928\u20132931, 1998","journal-title":"J Med Chem"},{"key":"247379_CR213","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1210\/endo.139.4.5902","volume":"139","author":"HZ Ke","year":"1998","unstructured":"Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WSS, Cameron KO, Rosati RL, Brown TA, Thompson DD: Effects of CP-336,156, a new, nonsteroidal estrogen agonist\/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models. Endocrinology 139: 2068\u20132076, 1998","journal-title":"Endocrinology"},{"key":"247379_CR214","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJM199608293350907","volume":"335","author":"PG Rose","year":"1996","unstructured":"Rose PG: Endometrial carcinoma. N Engl J Med 335: 640\u2013649, 1996","journal-title":"N Engl J Med"},{"key":"247379_CR215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1040-8428(96)00216-8","volume":"25","author":"GM Clinton","year":"1997","unstructured":"Clinton GM, Hua WH: Estrogen action in human ovarian cancer. Crit Rev Oncol Hematol 25: 1\u20139, 1997","journal-title":"Crit Rev Oncol Hematol"},{"key":"247379_CR216","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1046\/j.1525-1438.1997.00463.x","volume":"7","author":"C Marth","year":"1997","unstructured":"Marth C, Sorheim N, Kaern J, Trope C: Tamoxifen in the treatment of recurrent ovarian cancer. Int J Gynecol Cancer 7: 256\u2013261, 1997","journal-title":"Int J Gynecol Cancer"},{"key":"247379_CR217","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/1040-8428(92)90086-6","volume":"12","author":"DN Danforth Jr.","year":"1992","unstructured":"Danforth DN, Jr.: Hormone receptors inmalignancy. Crit Rev Oncol Hematol 12: 91\u2013149, 1992","journal-title":"Crit Rev Oncol Hematol"},{"key":"247379_CR218","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/(SICI)1097-0045(19980915)37:1<51::AID-PROS8>3.0.CO;2-B","volume":"37","author":"C Rohlff","year":"1998","unstructured":"Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, Hakim F, Trepel J, Bergan RC: Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1\/cip1). Prostate 37: 51\u201359, 1998","journal-title":"Prostate"},{"key":"247379_CR219","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V92.5.1749","volume":"92","author":"SP Treon","year":"1998","unstructured":"Treon SP, Teoh G, Urashima M, Ogata A, Chauhan D, Webb IJ, Anderson KC: Antiestrogens induce apoptosis of multiple myeloma cells. Blood 92: 1749\u20131757, 1998","journal-title":"Blood"},{"key":"247379_CR220","first-page":"1743","volume":"57","author":"LK Sampson","year":"1997","unstructured":"Sampson LK, Vickers SM, Ying WZ, Phillips JO: Tamoxifen-mediated growth inhibition of human cholangiocarcinoma. Cancer Res 57: 1743\u20131749, 1997","journal-title":"Cancer Res"},{"key":"247379_CR221","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s002800050612","volume":"39","author":"MM Gershanovich","year":"1997","unstructured":"Gershanovich MM, Moiseyenko VM, Vorobjev AV, Kapyla H, Ellmen J, Anttila M: High dose toremifene in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 39: 547\u2013551, 1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"247379_CR222","first-page":"S65","volume":"24","author":"EP Gelmann","year":"1997","unstructured":"Gelmann EP: Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 24: S65\u2013S70, 1997","journal-title":"Semin Oncol"},{"key":"247379_CR223","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0090-4295(96)00026-X","volume":"47","author":"JK Izes","year":"1996","unstructured":"Izes JK, Zinman LN, Larsen CR: Regression of large pelvic desmoid tumor by tamoxifen and sulindac. Urology 47: 756\u2013759, 1996","journal-title":"Urology"},{"key":"247379_CR224","first-page":"231","volume":"163","author":"G Tonietto","year":"1997","unstructured":"Tonietto G, Agresta F, Libera DD, Bittesini L: Treatment of idiopathic retroperitoneal fibrosis by tamoxifen. Eur J Surg 163: 231\u2013235, 1997","journal-title":"Eur J Surg"},{"key":"247379_CR225","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0014-5793(96)00782-X","volume":"392","author":"S Mosselman","year":"1996","unstructured":"Mosselman S, Polman J, Dijkema R: ERb: Identification and characterization of a novel human estrogen receptor. FEBS Lett 392: 49\u201353, 1996","journal-title":"FEBS Lett"},{"key":"247379_CR226","first-page":"4258","volume":"82","author":"E Enmark","year":"1997","unstructured":"Enmark E, PeltoHuikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA: Human estrogen receptor b-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82: 4258\u20134265, 1997","journal-title":"J Clin Endocrinol Metab"},{"key":"247379_CR227","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1006\/bbrc.1997.7893","volume":"243","author":"S Ogawa","year":"1998","unstructured":"Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M: The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 243: 122\u2013126, 1998","journal-title":"Biochem Biophys Res Commun"},{"key":"247379_CR228","first-page":"1486","volume":"11","author":"K Pettersson","year":"1997","unstructured":"Pettersson K, Grandien K, Kuiper GGJM, Gustafsson JA: Mwse estrogen receptor b forms estrogen response elementbinding heterodimers with estrogen receptor a. Mol Endocrinol 11: 1486\u20131496, 1997","journal-title":"Mol Endocrinol"},{"key":"247379_CR229","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0014-5793(97)00413-4","volume":"410","author":"GGJM Kuiper","year":"1997","unstructured":"Kuiper GGJM, Gustafsson JA: The novel estrogen receptorb subtype: Potential role in the cell-and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 410: 87\u201390, 1997","journal-title":"FEBS Lett"},{"key":"247379_CR230","doi-asserted-by":"crossref","first-page":"19858","DOI":"10.1074\/jbc.272.32.19858","volume":"272","author":"SM Cowley","year":"1997","unstructured":"Cowley SM, Hoare S, Mosselman S, Parker MG: Estrogen receptors a and b form heterodimers on DNA. J Biol Chem 272: 19858\u201319862, 1997","journal-title":"J Biol Chem"},{"key":"247379_CR231","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/mol.54.1.105","volume":"54","author":"T Barkhem","year":"1998","unstructured":"Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson JA, Nilsson S: Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonistslantagonists. Mol Pharnacol 54: 105\u2013112, 1998","journal-title":"Mol Pharnacol"},{"key":"247379_CR232","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.277.5331.1508","volume":"277","author":"K Paech","year":"1997","unstructured":"Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson JA, Kushner PJ, Scanlan TS: Differential activation of estrogen receptors ERa and ERb at AP1 sites. Science 277: 1508\u20131510, 1997","journal-title":"Science"},{"key":"247379_CR233","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1210\/jcem.82.7.4212","volume":"82","author":"H Dotzlaw","year":"1997","unstructured":"Dotzlaw H, Leygue E, Watson PH, Murphy LC: Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab 82: 2371\u20132374, 1997","journal-title":"J Clin Endocrinol Metab"},{"key":"247379_CR234","first-page":"529","volume":"59","author":"H Dotzlaw","year":"1999","unstructured":"Dotzlaw H, Leygue E, Watson PH, Murphy LC: Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins. Cancer Res 59: 529\u2013532, 1999","journal-title":"Cancer Res"},{"key":"247379_CR235","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1210\/endo.139.3.5840","volume":"139","author":"DN Petersen","year":"1998","unstructured":"Petersen DN, Tkalcevic GT, Koza-Taylor PH, Turi TG, Brown TA: Identification of estrogen receptor b2, a functional variant of estrogen receptor b expressed in normal rat tissues. Endocrinology 139: 1082\u20131092, 1998","journal-title":"Endocrinology"},{"key":"247379_CR236","first-page":"1175","volume":"59","author":"E Leygue","year":"1999","unstructured":"Leygue E, Dotzlaw H, Watson PH, Murphy LC: Expression of estrogen receptor beta 1, beta 2, and beta 5 messenger RNAs in human breast tissue. Cancer Res 59: 1175\u20131179, 1999","journal-title":"Cancer Res"},{"key":"247379_CR237","first-page":"136","volume":"55","author":"JA Fontana","year":"1987","unstructured":"Fontana JA: Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma ceil proliferation. Exp Cell Biol 55: 136\u2013144, 1987","journal-title":"Exp Cell Biol"},{"key":"247379_CR238","first-page":"4472","volume":"49","author":"TA Ratko","year":"1989","unstructured":"Ratko TA, Detrisac CJ, Dinger NM, Thomas CF, Kelloff GJ, Moon RC: Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 49: 4472\u20134476, 1989","journal-title":"Cancer Res"},{"key":"247379_CR239","first-page":"479","volume":"58","author":"ED Bischoff","year":"1998","unstructured":"Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW: Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 58: 479\u2013484, 1998","journal-title":"Cancer Res"},{"key":"247379_CR240","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jnci\/88.2.123","volume":"88","author":"MA Anzano","year":"1996","unstructured":"Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB: Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 88: 123\u2013125, 1996","journal-title":"J Natl Cancer Inst"},{"key":"247379_CR241","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/S0960-894X(97)00437-X","volume":"7","author":"LJ Farmer","year":"1997","unstructured":"Farmer LJ, Jeong S, Kallel EA, Koch SSC, Croston GE, Flatten KS, Heyman RA, Nadzan AM: Synthesis and structureactivity relationships of potent retinoid X receptor ligands. Bioorg Med Chem 7: 2393\u20132398, 1997","journal-title":"Bioorg Med Chem"},{"key":"247379_CR242","first-page":"935","volume":"18","author":"S Toma","year":"1998","unstructured":"Toma S, Isnardi L, Riccardi L, Bollag W: Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids. Anticancer Res 18: 935\u2013942, 1998","journal-title":"Anticancer Res"},{"key":"247379_CR243","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1097-2765(00)80047-7","volume":"1","author":"RM Evans","year":"1998","unstructured":"Evans RM, Fletcher C, Martin KJ, Mueller E, Sarraf P, Singer S, Spiegelman BM, Tontonoz P, Zhang M: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1: 465\u2013470, 1998","journal-title":"Mol Cell"},{"key":"247379_CR244","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1073\/pnas.95.15.8806","volume":"95","author":"E Elstner","year":"1998","unstructured":"Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95: 8806\u20138811, 1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"247379_CR245","first-page":"5711","volume":"54","author":"W. T. Vink-van","year":"1994","unstructured":"Vink-van Wijngaarden T, Pols HAP, Buurman CJ, Van den Bemd GJCM, Dorssers LCJ, Birkenh\u00e4ger JC, Van Leeuwen JPTM: Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 54: 5711\u20135717, 1994","journal-title":"Cancer Res"},{"key":"247379_CR246","first-page":"3370","volume":"58","author":"T Kubota","year":"1998","unstructured":"Kubota T, Koshizuka K, Koike M, Uskokovic M, Miyoshi I, Koeffler NP: 19-nor-26,27-bishomo-vitamin D-3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells. Cancer Res 58: 3370\u20133375, 1998","journal-title":"Cancer Res"},{"key":"247379_CR247","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1210\/mend.12.8.0146","volume":"12","author":"SK Lee","year":"1998","unstructured":"Lee SK, Choi HS, Song MR, Lee MO, Lee JW: Estrogen receptor, a common interaction partner for a subset of nuclear receptors. Mol Endocrinol 12: 1184\u20131192, 1998","journal-title":"Mol Endocrinol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006348907994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1006348907994\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006348907994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T20:19:27Z","timestamp":1753820367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1006348907994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,8]]},"references-count":247,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["247379"],"URL":"https:\/\/doi.org\/10.1023\/a:1006348907994","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,8]]}}}